[New aspects of primary radiochemotherapy in head and neck cancer : Highlights from the 2011 ASCO Congress].
Standard
[New aspects of primary radiochemotherapy in head and neck cancer : Highlights from the 2011 ASCO Congress]. / Laban, Simon; Wang, Chia-Jung; Knecht, Rainald; Tribius, Silke; Münscher, Adrian.
In: HNO, Vol. 60, No. 5, 5, 2012, p. 393-397.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - [New aspects of primary radiochemotherapy in head and neck cancer : Highlights from the 2011 ASCO Congress].
AU - Laban, Simon
AU - Wang, Chia-Jung
AU - Knecht, Rainald
AU - Tribius, Silke
AU - Münscher, Adrian
PY - 2012
Y1 - 2012
N2 - Primary radiochemotherapy is a treatment option for patients with locally advanced or unresectable head and neck cancer. Compared to conventional radiotherapy, intensity-modulated radiotherapy (IMRT) is associated with fewer long-term toxicities and better quality of life. Whether IMRT improves local control in these patients needs to be further investigated. The risk factors and treatment toxicities must be taken into consideration and discussed with the patients. New approaches combining radiotherapy and biological targets are a treatment option. The implementation of these substances in treatment protocols is increasing. Sensitive and specific prognostic biomarkers for patient identification to optimize treatment selection are important, but reliable parameters are still missing.
AB - Primary radiochemotherapy is a treatment option for patients with locally advanced or unresectable head and neck cancer. Compared to conventional radiotherapy, intensity-modulated radiotherapy (IMRT) is associated with fewer long-term toxicities and better quality of life. Whether IMRT improves local control in these patients needs to be further investigated. The risk factors and treatment toxicities must be taken into consideration and discussed with the patients. New approaches combining radiotherapy and biological targets are a treatment option. The implementation of these substances in treatment protocols is increasing. Sensitive and specific prognostic biomarkers for patient identification to optimize treatment selection are important, but reliable parameters are still missing.
M3 - SCORING: Zeitschriftenaufsatz
VL - 60
SP - 393
EP - 397
JO - HNO
JF - HNO
SN - 0017-6192
IS - 5
M1 - 5
ER -
